NCT07354516CompletedPhase 2/3
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 64 (actual)
- First submitted
- 17 Jan 2026
- Start date
- 18 Mar 2026
- Primary completion date
- 22 Jul 2026
- Lead sponsor
- Qlaris Bio, Inc.
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT07354516
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 64
- From 18 Mar 2026 to the primary completion date, 22 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of any topical PGA without a clinically meaningful response
- Noncompliant with current ocular anti-hypertensive medications or unwilling to be compliant throughout the study
- Use of other topical ocular concomitant medications 30 days prior
- Participation in any investigational study within 30 days prior to Screening
Other illness
- History of active ocular disease other than mild to moderate OAG/OHT
- History of angle closure or a narrow angle, significant ocular trauma, ocular infection, uveitis, intraocular surgery in either eye.
- Clinically significant systemic or psychiatric disease, chronic kidney disease, or hypertension, hypotension, or diabetes that is uncontrolled.
Other
- Central corneal thickness in either eye \<470 or \>630 μm
- Females who are pregnant, nursing, or not using birth control.
Who the study is looking for
- BCVA 1.0 logMAR or better in each eye (equivalent to 20/200)
- Diagnosis of mild to moderate OAG or OHT in at least one eye
- IOP ≥19 mmHg at 08:00 hour (H) at Qualification Visits following a run-in with PF latanoprost
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shettle Eye Research Coordinator of this site? Confirm its status | Largo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.